ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
FDA approves Nulibry to treat Molybdenum Cofactor Deficiency Type A
March 02, 2021The US Food and Drug Administration (FDA) has approved BridgeBio Pharma and Origin Biosciences’ Nulibry (fosdenopterin), making it the first treatment to be authorised to reduce the risk of mortality in patients with molybdenum cofactor deficiency ... -
BridgeBio Pharma LLC Signs Joint Collaboration Agreement with Cincinnati Children's to Accelerate Development of Genetic Disease Therapeutics
November 13, 2018"BridgeBio is privileged to partner with leading experts at Cincinnati Children's, an institution whose impact on science and patients we admire. We hope we can help advance the mission by partnering to move therapies forward to patients," said Neil Kumar -
BridgeBio Launches CoA Therapeutics
June 19, 2018BridgeBio Pharma announced the launch of CoA Therapeutics, a biopharmaceutical company developing novel small-molecules designed to increase Coenzyme-A (CoA) levels in genetic disorders where CoA deficiency is implicated. -
BridgeBio Launches QED Therapeutics With $65M and an Abandoned Novartis Cancer Program
January 31, 2018Palo Alto, Calif.-based BridgeBio Pharma is launching a new spinout to develop a recently-abandoned Novartis cancer treatment now in its possession.
Pharma Sources Insight January 2025
